XM does not provide services to residents of the United States of America.
A
A

Amphenol

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. Edwards Lifesciences, National Bank Holdings, Sage Therapeutics

U.S. RESEARCH ROUNDUP-Edwards Lifesciences, National Bank Holdings, Sage Therapeutics July 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Edwards Lifesciences, National Bank Holdings and Sage Therapeutics, on Thursday. HIGHLIGHTS * Edwards Lifesciences Corp EW.N : JP Morgan cuts to neutral from overweight * National Bank Holdings Corp NBHC.N : Piper Sandler cuts to neutral from overweight * Sage Therapeutics Inc S
A
A
C
C
G
S
C
E
H
I
A
A
E
L

Amphenol sees third-quarter revenue below estimates on weak equipment demand

UPDATE 1-Amphenol sees third-quarter revenue below estimates on weak equipment demand Rewrites throughout July 24 (Reuters) - Electronic equipment maker Amphenol APH.N forecast third-quarter revenue below market estimates on Wednesday, as customers across broadband and industrial markets scale back on spending in the face of high borrowing costs. Shares of the Wallingford, Connecticut-based company fell 4.2% in early trading.
A

Amphenol beats Q2 revenue on steady demand for defense, communication equipment

Amphenol beats Q2 revenue on steady demand for defense, communication equipment July 24 (Reuters) - Electronic equipment maker Amphenol APH.N beat market estimates for second-quarter sales on Wednesday, on the back of growing demand for defense and communication equipment. Amid the dynamic geopolitical environment, countries across the globe are expanding their investments in next-generation defense technologies.
A

Amphenol Q2 Sales USD 3,609.7 Million Vs. IBES Estimate USD 3,390 Million

BRIEF-Amphenol Q2 Sales USD 3,609.7 Million Vs. IBES Estimate USD 3,390 Million Jul 24 (Reuters) - Amphenol Q2 operating income USD 698.8 million. Q2 gross profit USD 1,213.1 million Q2 net income USD 528.7 million Q2 EPS USD 0.41 Q2 adjusted EPS USD 0.44 outlook Q3 adjusted EPS USD 0.43-0.45 outlook Q3 revenue USD 3,700-3,800 million
A

U.S. Colgate-Palmolive, McKesson, Microsoft

U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft July 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Colgate-Palmolive, McKesson and Microsoft, on Tuesday. HIGHLIGHTS * Colgate-Palmolive Co CL.N : TD Cowen initiates coverage with buy rating; PT $110 * DR Horton Inc DHI.N : JP Morgan raises target price to $180 from $163 * IQVIA Holdings Inc IQV.N : Baird raises target price to $251 from $235 * McKesso
C
H
M
M
T
V
Z
F
A
M
A
C
C
D
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.